Navigation Links
Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
Date:9/4/2013

MALVERN, Pa. and RALEIGH, N.C., Sept. 4, 2013 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), and BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that the companies have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine. 

The interim analyses were conducted as part of the Phase III protocol to allow for adjustments to the sample size in order to maintain appropriate study power to detect statistically significant differences between BEMA Buprenorphine and placebo.  The analyses were conducted by an independent biostatistician.

Endo and BDSI view the outcomes of the interim analyses as encouraging. As a result of the interim analyses, it was determined that no sample size adjustment will be necessary to the opioid naive study.  Additional patients will be added to the ongoing opioid experienced trial to maintain appropriate power to allow for the detection of a statistically significant difference between BEMA Buprenorphine and placebo based on the primary efficacy endpoint.

"We are encouraged by the outcomes of the interim analyses which were conducted to determine if the original sample size assumptions were appropriate and to allow for adjustments to the study sample size to preserve appropriate study power," stated Dr. Ivan Gergel, executive vice president of research & development at Endo.  "As a leader in the treatment of chronic pain we are excited about the potential for BEMA Buprenorphine as one of our lead development programs for our branded pharmaceuticals business."

"The outcomes of the interim analyses are sign
'/>"/>

SOURCE Endo Pharmaceuticals Inc.; BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
2. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
3. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
4. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
5. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
6. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
7. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
9. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
10. BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... VRUS ), a clinical stage pharmaceutical company ... treat viral,infections, reported unaudited financial results for the ... Pharmasset reported a net loss,attributable to common stockholders ... first fiscal quarter of 2008, as compared to ...
... Software & Database Developed in West ... Treatment Options, VENLO, Netherlands and GRAND RAPIDS, ... (CMM) today announced the formation of a,collaborative effort ... Prime Standard: QIA) to support research focused on ...
Cached Medicine Technology:Pharmasset Reports First Fiscal Quarter 2008 Financial Results 2Pharmasset Reports First Fiscal Quarter 2008 Financial Results 3Pharmasset Reports First Fiscal Quarter 2008 Financial Results 4Pharmasset Reports First Fiscal Quarter 2008 Financial Results 5Pharmasset Reports First Fiscal Quarter 2008 Financial Results 6Pharmasset Reports First Fiscal Quarter 2008 Financial Results 7Pharmasset Reports First Fiscal Quarter 2008 Financial Results 8QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 2QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 3QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 4
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Adults with dyslexia are more ... children or teenagers than people who don,t have the ... Dyslexia, which affects up to 10 percent of people, ... 35 percent of adults with this condition said they ... percent of those without dyslexia. "Even after accounting ...
(Date:7/10/2014)... Kristen Fischer HealthDay ... Slimming down may help ease the hot flashes that often ... debilitating for more than 50 percent of menopausal women, said ... and reproductive science at the Icahn School of Medicine at ... menopausal women experience more than 10 hot flashes a day, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... that break out regularly between outspoken celebrities or loudmouth pundits ... relationship, a new study suggests. High amounts of Twitter ... the couple is in a long-term relationship, according to findings ... turn, that friction can lead to cheating and breakups, the ...
Breaking Medicine News(10 mins):Health News:Study finds widespread oral health problems among Navajo 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... Patient Care Model Significantly Improves Patient OutcomesEL SEGUNDO, ... provider of kidney care services for those diagnosed ... findings of a study revealing DaVita,s IMPACT(TM) (Incident ... program can significantly reduce mortality rates for new ...
... Pediatric surgeons are able to repair complex heart defects ... but that doesn,t necessarily mean a happy ending for ... great quality of life and others, with the same ... pediatric medical centers throughout the United States shows that ...
... HOUSTON (March 29, 2009) The allergen breathed in by ... MMP7 that activates a cascade of events to prompt an ... College of Medicine ( www.bcm.edu ) in Houston in a ... Immunology . , In particular, MMP7 activates interleukin 25, a ...
... the same for bare metal or drug-eluting devices, study found, ... that stent thrombosis, a blood clot inside a stent, is ... no difference in the clot risk for either drug-eluting ... After a heart attack, many patients undergo a treatment ...
... Health Ltd. affiliate program is the answer for individuals who want to ... benefits as well as demand. ZEO Health has created a risk-free, ... today and find out more about the affiliate program. , ... New ...
... Michael Harbut, M.D., MPH, co-director of the National ... Barbara Ann Karmanos Cancer Institute in Detroit, MI, and ... Wayne State University , announced the use of ... asbestos-related lung disease. The announcement was made at the ...
Cached Medicine News:Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 2Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 3Health News:Physicians mending broken hearts 2Health News:No Increase in Clots With Drug-Eluting Stents 2Health News:No Increase in Clots With Drug-Eluting Stents 3Health News:ZEO Health's New Program Offers Answer for Those Looking for Income 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3
Nitinol Flat Wire Basket...
A breakaway microwell EIA for the detection of toxins produced by Enterohemorrhagic E. coli...
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Medicine Products: